"For decades, the American government has played a powerful but disciplined role in healthcare markets. At first, it was a passive purchaser, then a coverage expander, and only recently has it become a price negotiator, albeit in a limited capacity. However, TrumpRx, which seeks for pharmaceutical companies to grant the U.S. "most favored nation" status, is a departure from these models and signals a continued shift toward government market interventionism."
"TrumpRx also emerges in a political environment where government intervention in drug pricing is no longer considered unacceptable. While the passage of the Inflation Reduction Act (IRA) marked a small first step toward addressing a malady, Trump has made government intrusion into market operations a standard tool for his version of the Republican Party to "correct" perceived failures. What was once labeled "price control" is now cannily framed as an affordability reform."
TrumpRx is a president-led direct-to-patient platform that aims to restructure pharmaceutical markets by seeking 'most favored nation' pricing from manufacturers. The initiative marks a distinct move from past government roles that ranged from passive purchaser to limited price negotiator, signaling increased market intervention. The political climate, including passage of the Inflation Reduction Act, has normalized greater government involvement in drug pricing and rebranded price controls as affordability reforms. Early analysis indicates only a small subset of patients will benefit from TrumpRx, while the majority of Americans are unlikely to see lower drug prices. Stakeholder reactions reflect concern about market and patient-care impacts.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]